300142 沃森生物
交易中 05-28 14:06:24
资讯
新帖
简况
沃森生物：公司将在股东会审议通过后2个月内完成本次权益分派的实施
证券之星 · 05-19
沃森生物：公司将在股东会审议通过后2个月内完成本次权益分派的实施
沃森生物：利用已上市或处于临床研究阶段的疫苗产品大力开发针对婴幼儿的联合疫苗
证券之星 · 05-11
沃森生物：利用已上市或处于临床研究阶段的疫苗产品大力开发针对婴幼儿的联合疫苗
股市必读：沃森生物（300142）5月8日披露最新机构调研信息
证券之星 · 05-11
股市必读：沃森生物（300142）5月8日披露最新机构调研信息
沃森生物：5月8日接受机构调研，中金公司研究部、Dymon Asia参与
证券之星 · 05-09
沃森生物：5月8日接受机构调研，中金公司研究部、Dymon Asia参与
沃森生物：本次发行相关事项的生效和完成尚需国家市场监督管理总局经营者集中申报审查通过（如需）、深圳证券交易所审核通过并需经中国证监会同意注册等其他必需的行政审批机关批准后方可实施
证券之星 · 05-07
沃森生物：本次发行相关事项的生效和完成尚需国家市场监督管理总局经营者集中申报审查通过（如需）、深圳证券交易所审核通过并需经中国证监会同意注册等其他必需的行政审批机关批准后方可实施
每周股票复盘：沃森生物（300142）Q1净利增4082.41%
证券之星 · 05-03
每周股票复盘：沃森生物（300142）Q1净利增4082.41%
4月28日沃森生物涨7.53%，疫苗ETF嘉实基金重仓该股
证券之星 · 04-28
4月28日沃森生物涨7.53%，疫苗ETF嘉实基金重仓该股
沃森生物最新公告：第一季度净利润同比增长4082.41%
证券之星 · 04-27
沃森生物最新公告：第一季度净利润同比增长4082.41%
沃森生物：公司通过新冠mRNA疫苗的研发与合作方一起建立了mRNA疫苗技术平台
证券之星 · 04-16
沃森生物：公司通过新冠mRNA疫苗的研发与合作方一起建立了mRNA疫苗技术平台
沃森生物：持续深化营销体系改革
证券之星 · 04-15
沃森生物：持续深化营销体系改革
沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段
证券之星 · 04-10
沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段
A股收评：美伊停火引爆！沪指剑指4000点，贵金属、AI应用爆发
格隆汇 · 04-08
A股收评：美伊停火引爆！沪指剑指4000点，贵金属、AI应用爆发
沃森生物（300142）披露2026年第二次临时股东会决议公告，4月3日股价下跌2.68%
证券之星 · 04-03
沃森生物（300142）披露2026年第二次临时股东会决议公告，4月3日股价下跌2.68%
沃森生物资本腾挪背后：业绩下滑现金却被大幅消耗？少数股东“低买高卖”谁在套利
新浪证券 · 04-03
沃森生物资本腾挪背后：业绩下滑现金却被大幅消耗？少数股东“低买高卖”谁在套利
沃森生物：持续加强与全球健康组织和海外生物药企的交流与合作
证券之星 · 03-30
沃森生物：持续加强与全球健康组织和海外生物药企的交流与合作
股市必读：沃森生物年报 - 第四季度单季净利润同比增长112.52%
证券之星 · 03-30
股市必读：沃森生物年报 - 第四季度单季净利润同比增长112.52%
沃森生物(300142.SZ)发布2025年度业绩，归母净利润1.78亿元，增长25.03%
智通财经 · 03-27
沃森生物(300142.SZ)发布2025年度业绩，归母净利润1.78亿元，增长25.03%
沃森生物等来的不是招商局，而是一家北京地产商
蓝鲸财经 · 03-27
沃森生物等来的不是招商局，而是一家北京地产商
三月已有3起深交所上市公司控制权交易买方锁定60个月
文艺馥欣 · 03-26
三月已有3起深交所上市公司控制权交易买方锁定60个月
“落难”疫苗明星打折定增，沃森生物能否逆风翻盘？
微博财经-财道工作室 · 03-24
“落难”疫苗明星打折定增，沃森生物能否逆风翻盘？
加载更多
公司概况
公司名称：
云南沃森生物技术股份有限公司
所属行业：
医药制造业
上市日期：
2010-11-12
主营业务：
云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是13价肺炎结合疫苗、双价HPV疫苗、23价肺炎多糖疫苗、b型流感嗜血杆菌结合疫苗、A群C群脑膜炎球菌多糖结合疫苗、ACYW135群脑膜炎球菌多糖疫苗、A群C群脑膜炎球菌多糖疫苗、吸附无细胞百白破联合疫苗。公司是中国首家、全球第二家自主研发并成功上市13价肺炎结合疫苗的企业，也是中国第二家、全球第四家自主研发并成功上市HPV疫苗的企业。
发行价格：
95.00
{"stockData":{"symbol":"300142","market":"SZ","secType":"STK","nameCN":"沃森生物","latestPrice":13.29,"timestamp":1779948384000,"preClose":13.25,"halted":0,"volume":46336316,"delay":0,"changeRate":0.003,"floatShares":1577000000,"shares":1599000000,"eps":0.1787,"marketStatus":"交易中","change":0.04,"latestTime":"05-28 14:06:24","open":13.17,"high":13.37,"low":13,"amount":611000000,"amplitude":0.0279,"askPrice":13.3,"askSize":63,"bidPrice":13.29,"bidSize":610,"shortable":0,"etf":0,"ttmEps":0.1787,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1779951600000},"marketStatusCode":2,"adr":0,"adjPreClose":13.25,"symbolType":"stock","openAndCloseTimeList":[[1779931800000,1779939000000],[1779944400000,1779951600000]],"highLimit":14.58,"lowLimit":11.93,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1599348541,"isCdr":false,"pbRate":2.86,"roa":"--","peRate":74.370453,"roe":"1.41%","epsLYR":0.1111,"committee":0.210122,"marketValue":21255000000,"turnoverRate":0.0294,"status":0,"floatMarketCap":20957000000},"requestUrl":"/m/hq/s/300142/","defaultTab":"news","newsList":[{"id":"2636348888","title":"沃森生物：公司将在股东会审议通过后2个月内完成本次权益分派的实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2636348888","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636348888?lang=zh_cn&edition=full","pubTime":"2026-05-19 08:42","pubTimestamp":1779151336,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物(300142)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司何时分红沃森生物回复：尊敬的投资者，您好！公司已于2026年4月29日召开2025年年度股东会，审议通过2025年年度权益分派事项，公司将在股东会审议通过后2个月内完成本次权益分派的实施，具体实施时间请关注公司后续披露的公告。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900009174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0077","300142","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634703409","title":"沃森生物：利用已上市或处于临床研究阶段的疫苗产品大力开发针对婴幼儿的联合疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2634703409","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634703409?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:42","pubTimestamp":1778488933,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物05月11日在投资者关系平台上答复投资者关心的问题。在疫苗产品研发上，公司一方面将持续加强目前已上市品种的产品升级，开发更高价次肺炎球菌多糖结合疫苗、更高价次脑膜炎球菌疫苗、更高价次HPV疫苗，并进一步扩大适用人群范围；另一方面将不断加快创新性疫苗的研发布局，同时，利用已上市或处于临床研究阶段的疫苗产品大力开发针对婴幼儿的联合疫苗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100022348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0077","BK0070","300142","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634425515","title":"股市必读：沃森生物（300142）5月8日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2634425515","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634425515?lang=zh_cn&edition=full","pubTime":"2026-05-11 01:48","pubTimestamp":1778435296,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，沃森生物报收于13.35元，上涨1.52%，换手率4.95%，成交量78.07万手，成交额10.45亿元。当日关注点来自交易信息汇总：5月8日主力资金净流入1834.41万元，游资资金同步净流入，散户资金呈净流出态势。来自机构调研要点：5月8日公司召开电话会议，副总裁、董事会秘书等高管参与交流。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100000869.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0046","BK0070","300142","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634495239","title":"沃森生物：5月8日接受机构调研，中金公司研究部、Dymon Asia参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2634495239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634495239?lang=zh_cn&edition=full","pubTime":"2026-05-09 09:03","pubTimestamp":1778288597,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年5月8日沃森生物发布公告称公司于2026年5月8日接受机构调研，中金公司研究部杨一正、Dymon AsiaBen Wei Wang Pei参与。沃森生物2026年一季报显示，一季度公司主营收入4.44亿元，同比下降3.98%；归母净利润1.11亿元，同比上升4082.41%；扣非净利润1.14亿元，同比上升1089.2%；负债率29.79%，投资收益-23.82万元，财务费用359.15万元，毛利率68.47%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050900004425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1564","LU1508157978.USD","LU0359202008.SGD","601995","BK1147","LU1023057109.AUD","BK0046","LU2663582299.SGD","LU1580142542.USD","BK0239","LU0359201612.USD","BK0077","BK0276","SG9999002828.SGD","LU0359201885.HKD","BK0070","LU1781817850.SGD","BK1516","03908","300142","BK1501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633118072","title":"沃森生物：本次发行相关事项的生效和完成尚需国家市场监督管理总局经营者集中申报审查通过（如需）、深圳证券交易所审核通过并需经中国证监会同意注册等其他必需的行政审批机关批准后方可实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2633118072","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633118072?lang=zh_cn&edition=full","pubTime":"2026-05-07 15:42","pubTimestamp":1778139733,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物(300142)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问：请问腾云新沃的投资款到位了吗？沃森生物回复：尊敬的投资者，您好！本次发行相关事项的生效和完成尚需国家市场监督管理总局经营者集中申报审查通过（如需）、深圳证券交易所审核通过并需经中国证监会同意注册等其他必需的行政审批机关批准后方可实施。敬请广大投资者注意投资风险。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700020344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","399001","BK0077","BK0070","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632670663","title":"每周股票复盘：沃森生物（300142）Q1净利增4082.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632670663","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632670663?lang=zh_cn&edition=full","pubTime":"2026-05-03 06:42","pubTimestamp":1777761735,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，沃森生物报收于13.0元，较上周的11.88元上涨9.43%。本周，沃森生物4月28日盘中最高价报13.61元。本周关注点来自业绩披露要点：沃森生物2026年一季报归母净利润1.11亿元，同比上升4082.41%。股本股东变化股东户数变动截至2026年3月31日，沃森生物股东户数为11.84万户，较2月28日减少319.0户，减幅0.27%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300001604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300142","BK0239","BK0046","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630376329","title":"4月28日沃森生物涨7.53%，疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630376329","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630376329?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:33","pubTimestamp":1777365189,"startTime":"0","endTime":"0","summary":"证券之星消息，4月28日沃森生物涨7.53%，收盘报12.85元，换手率10.41%，成交量162.42万手，成交额21.22亿元。重仓沃森生物的前十大公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共11家，其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.25亿元，最新净值0.6836，较上一交易日上涨0.15%，近一年上涨13.79%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800049268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0070","300142","BK0046","562860","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630364349","title":"沃森生物最新公告：第一季度净利润同比增长4082.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630364349","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630364349?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:36","pubTimestamp":1777282608,"startTime":"0","endTime":"0","summary":"沃森生物公告称，2026年第一季度实现营业收入4.44亿元，同比下降3.98%；归属于上市公司股东的净利润为1.11亿元，同比增长4082.41%。业绩变动主要系公司根据行业情况及实际业务情况变更应收账款预期信用损失会计估计，导致应收账款坏账准备计提金额下降，以及本期转回坏账准备所致；同时，公司20价肺炎球菌多糖结合疫苗和新型冠状病毒变异株mRNA疫苗项目已达到资本化阶段，而上年同期处于费用化阶段，致使研发费用减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700032614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627126330","title":"沃森生物：公司通过新冠mRNA疫苗的研发与合作方一起建立了mRNA疫苗技术平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2627126330","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627126330?lang=zh_cn&edition=full","pubTime":"2026-04-16 11:48","pubTimestamp":1776311288,"startTime":"0","endTime":"0","summary":"从全球来看，mRNA创新技术平台历经数十年技术沉淀，打破了传统疫苗研发模式的限制，过去几年，全球创新疫苗企业借助该技术已累计创造了较高的商业价值。经过多年的持续投入，中国创新疫苗企业也已建立了自己的mRNA疫苗技术平台，部分疫苗企业已在多款mRNA疫苗上有研发布局。关于公司mRNA疫苗平台建设及相关产品的后续进展情况请持续关注公司的信息披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600018568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0070","159646","BK0046","BK0239","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627475367","title":"沃森生物：持续深化营销体系改革","url":"https://stock-news.laohu8.com/highlight/detail?id=2627475367","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627475367?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:36","pubTimestamp":1776213369,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物04月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司13价肺炎结合疫苗连续多年保持国内市场份额第一，2026年在基层市场下沉和成人适应症拓展方面有哪些具体规划？同时，加强与全球健康组织和海外生物药企的交流与合作，采取多元化合作模式，持续深入推进产品在海外市场的注册和出口，保持海外业务的高质量发展态势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500008863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0046","BK0077","BK0070","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626154347","title":"沃森生物：公司九价HPV疫苗目前处于III期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2626154347","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626154347?lang=zh_cn&edition=full","pubTime":"2026-04-10 09:03","pubTimestamp":1775782990,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物(300142)04月09日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司九价HPV疫苗进入大三期临床了吗？什么是大三期？从三期临床开始到疫苗上市都有哪些环节？贵司九价HPV疫苗目前处于哪个环节？沃森生物回复：尊敬的投资者，您好！公司九价HPV疫苗目前处于III期临床研究阶段，公司将按照国家对于注册临床试验的有关程序和要求推进相关工作。关于相关产品的后续进展情况请持续关注公司披露的信息。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000007760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300142","BK0046","159646","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625691560","title":"A股收评：美伊停火引爆！沪指剑指4000点，贵金属、AI应用爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2625691560","media":"格隆汇","labels":["economic"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625691560?lang=zh_cn&edition=full","pubTime":"2026-04-08 15:42","pubTimestamp":1775634144,"startTime":"0","endTime":"0","summary":"全市场成交额2.45万亿元，超5100股上涨","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/101.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/101.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d4621a4347f62f73217129ec8b33f217","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4338263","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["000688.SH","510880","BK4585","000300.SH","512880","399001","300142","300418","XAUUSD.FOREX","GLD","000001","BK4588","159967","300308","512510","000905.SH","000607","399006","515890","510300"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2624668743","title":"沃森生物（300142）披露2026年第二次临时股东会决议公告，4月3日股价下跌2.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624668743","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624668743?lang=zh_cn&edition=full","pubTime":"2026-04-03 22:10","pubTimestamp":1775225427,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，沃森生物报收于12.35元，较前一交易日下跌2.68%，最新总市值为197.52亿元。该股当日开盘12.62元，最高12.7元，最低12.29元，成交额达4.79亿元，换手率为2.48%。近日，云南沃森生物技术股份有限公司发布《2026年第二次临时股东会决议公告》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300043270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0046","BK0239","BK0077","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624652646","title":"沃森生物资本腾挪背后：业绩下滑现金却被大幅消耗？少数股东“低买高卖”谁在套利","url":"https://stock-news.laohu8.com/highlight/detail?id=2624652646","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624652646?lang=zh_cn&edition=full","pubTime":"2026-04-03 19:19","pubTimestamp":1775215140,"startTime":"0","endTime":"0","summary":"值得注意的是，少数股权在上述系列腾挪或成功上演了““低买高卖”式套利，即在标的产品即将上市前夕精准相对低价入股，随着业绩持续缩水又相对高价卖给上市公司。这一系列资本腾挪背后究竟有没有利益输送？ 近日，沃森生物发布2025年年报，业绩处在持续下滑“泥潭”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-04-03/doc-inhtfres0174173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","BK0070","BK0239","300142","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623390485","title":"沃森生物：持续加强与全球健康组织和海外生物药企的交流与合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2623390485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623390485?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:45","pubTimestamp":1774860330,"startTime":"0","endTime":"0","summary":"证券之星消息，沃森生物03月30日在投资者关系平台上答复投资者关心的问题。公司持续加强与全球健康组织和海外生物药企的交流与合作，采取多元化合作模式，深入推进产品在海外市场的注册和出口业务，并加快海外本地化产业项目的建设，不断拓展海外市场，为公司和股东创造价值。关于公司国际业务的开展情况请持续关注公司披露的相关公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000022081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0077","300142","BK0070","BK0239","159839"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623350914","title":"股市必读：沃森生物年报 - 第四季度单季净利润同比增长112.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623350914","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623350914?lang=zh_cn&edition=full","pubTime":"2026-03-30 03:34","pubTimestamp":1774812852,"startTime":"0","endTime":"0","summary":"股本股东变化股东户数变动截至2026年2月28日，公司股东户数为11.88万户，较2025年12月31日增加5798.0户，增幅5.13%。2025年第四季度单季度主营收入6.99亿元，同比增长2.84%；单季度归母净利润1429.86万元，同比增长112.52%；单季度扣非净利润2491.08万元，同比增长121.56%。公司公告汇总2025年年度报告摘要2025年公司实现营业收入24.18亿元，同比下降14.29%；归母净利润1.78亿元，同比增长25.03%；扣非净利润9545.09万元，同比下降11.94%。自主疫苗产品销售收入21.52亿元，占总收入89%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000000725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622828568","title":"沃森生物(300142.SZ)发布2025年度业绩，归母净利润1.78亿元，增长25.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622828568","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622828568?lang=zh_cn&edition=full","pubTime":"2026-03-27 18:37","pubTimestamp":1774607832,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沃森生物(300142.SZ)发布2025年年度报告，该公司营业收入为24.18亿元，同比减少14.29%。归属于上市公司股东的净利润为1.78亿元，同比增长25.03%。归属于上市公司股东的扣除非经常性损益的净利润为9545.09万元，同比减少11.94%。基本每股收益为0.1111元。此外，拟向全体股东每10股派发现金红利1.25元(含税)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622681577","title":"沃森生物等来的不是招商局，而是一家北京地产商","url":"https://stock-news.laohu8.com/highlight/detail?id=2622681577","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622681577?lang=zh_cn&edition=full","pubTime":"2026-03-27 09:58","pubTimestamp":1774576734,"startTime":"0","endTime":"0","summary":"沃森生物日前披露，公司正在筹划定增，可能导致控制权发生变更。然而，沃森生物最终等来的，却是一家远在北京的民营地产商。深陷多重困境的沃森生物，此次定增，既是无奈之举，也是主动求生。此次入主沃森生物，是黄涛在大健康赛道落下的重要一子。本次发行完成后，腾云新沃将直接持有沃森生物11.51%股权，成为第一大股东。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1774339767435771318","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0070","BK0077","BK0239","300142","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622869852","title":"三月已有3起深交所上市公司控制权交易买方锁定60个月","url":"https://stock-news.laohu8.com/highlight/detail?id=2622869852","media":"文艺馥欣","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622869852?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:01","pubTimestamp":1774533660,"startTime":"0","endTime":"0","summary":"我们观察到3月已有3起深交所上市公司控制权交易，收购方自愿性承诺股份锁定60个月，并且在股权质押、资产注入安排等方面也有所收紧，呈现出沪深交易所要求趋同的现象，这一要求是否将持续以及所传递的信号值得高度关注。腾云新沃成为公司控股股东，黄涛将成为公司实际控制人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-03-26/doc-inhsiqkn0141820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0081","300385","002569","BK0028","300142","BK0070","BK0160","BK0004","BK0046","BK0102","BK0239","BK0150","BK0253","BK0251","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621095555","title":"“落难”疫苗明星打折定增，沃森生物能否逆风翻盘？","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095555","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621095555?lang=zh_cn&edition=full","pubTime":"2026-03-24 22:20","pubTimestamp":1774362000,"startTime":"0","endTime":"0","summary":"困局还是必然选择在资本市场中，定增折价并不罕见，但沃森生物此次超过20%的折价幅度，仍让不少投资者感到意外。与此同时，沃森生物在九价HPV疫苗、mRNA带状疱疹疫苗上的每年研发费用均保持在较高水平，进一步加剧了资金压力。从现金流来看，沃森生物的资金状况也不容乐观。此次定增后，黄涛通过腾云新沃及一致行动人持有14.46%的表决权，成为沃森生物绝对控股股东，而创始人李云春直接持股仅1.70%，持股比例极低。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2026-03-24/doc-inhscaeq1631327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0070","300142","BK0046","159646","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779948386774,"stockEarnings":[{"period":"1week","weight":-0.0549},{"period":"1month","weight":0.1088},{"period":"3month","weight":0.0852},{"period":"6month","weight":0.0925},{"period":"1year","weight":0.3025},{"period":"ytd","weight":0.2176}],"compareEarnings":[{"period":"1week","weight":-0.0164},{"period":"1month","weight":0.0018},{"period":"3month","weight":-0.0128},{"period":"6month","weight":0.0528},{"period":"1year","weight":0.2254},{"period":"ytd","weight":0.0315}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"云南沃森生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"118448人(较上一季度减少0.27%)","perCapita":"13313股","listingDate":"2010-11-12","address":"云南省昆明市五华区高新区科新路395号","registeredCapital":"159934万元","survey":" 云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是13价肺炎结合疫苗、双价HPV疫苗、23价肺炎多糖疫苗、b型流感嗜血杆菌结合疫苗、A群C群脑膜炎球菌多糖结合疫苗、ACYW135群脑膜炎球菌多糖疫苗、A群C群脑膜炎球菌多糖疫苗、吸附无细胞百白破联合疫苗。公司是中国首家、全球第二家自主研发并成功上市13价肺炎结合疫苗的企业，也是中国第二家、全球第四家自主研发并成功上市HPV疫苗的企业。","listedPrice":95},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沃森生物,300142,沃森生物股票,沃森生物股票老虎,沃森生物股票老虎国际,沃森生物行情,沃森生物股票行情,沃森生物股价,沃森生物股市,沃森生物股票价格,沃森生物股票交易,沃森生物股票购买,沃森生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}